Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Mesoblast Limited ( (AU:MSB) ) has provided an update.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Mesoblast Limited, acquiring a 5.03% voting power in the company as of May 9, 2025. This development may influence Mesoblast’s market positioning and stakeholder interests, as JPMorgan’s involvement could bring increased financial scrutiny and potential strategic opportunities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development of innovative cellular medicines. The company is primarily engaged in developing treatments for inflammatory diseases, cardiovascular diseases, and back pain, leveraging its proprietary mesenchymal lineage adult stem cell technology.
Average Trading Volume: 6,866,456
Technical Sentiment Signal: Hold
Current Market Cap: A$2.2B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.